A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
Crossref DOI link: https://doi.org/10.1186/s12885-017-3492-1
Published Online: 2017-07-25
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Decker, Thomas
Overkamp, Friedrich
Rösel, Siegfried
Nusch, Arnd
Göhler, Thomas
Indorf, Martin
Sahlmann, Jörg
Trarbach, Tanja
Funding for this research was provided by:
Bayer
